Ethypharm acquires DB Ashbourne in the UK

Published: 2-Oct-2015
Finance Pharmaceutical

Acquisition will generate a turnover of more than €240m for Ethypharm


Ethypharm has acquired 100% of the share capital of DBA Group, a branded pharmaceutical business established in the UK in 2009. DBA currently markets and supplies a range of prescription-only medicines to the UK market, and has an exciting pipeline of products in development, which will be supplemented with a wide range of additional products from Ethypharm.

With the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addiction. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a turnover of more than €240m for Ethypharm.

‘I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic, and DBA offers a great platform to launch products from our own pipeline,’ said Hugues Lecat, CEO of Ethypharm.

  • Companies:
  • Ethypharm SA
See more

You may also like

Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Read more
Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection

Trending Articles

  1. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  2. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  3. How pharma packaging manufacturers role is evolving: the case of extractables testing As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
  4. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  5. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection
Drug Delivery

French Ethypharm acquires Martindale Pharma

Independent pharmaceutical company Ethypharm reinforces its UK presence by acquiring Martindale Pharma
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The new fight against diabetes and obesity

Incretin mimetics administered by autoinjectors or pens enable significant weight reduction and offer an important way to combat obesity and prevent type 2 diabetes. As such, pharmaceutical manufacturers are currently investing heavily in development and production
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Subscribe now